Business ❯ Biotechnology

Drug Development

Clinical Trials Artificial Intelligence Clinical Research Autoimmune Diseases Regulatory Affairs AI in Healthcare Regulatory Compliance Contract Research Organizations Commercial Assets Neuro-immunology Axovant Sciences Pharmaceutical Industry Animal Health Immunotherapy Collaborations Lifespan Extension Market Competition Therapies Pharmaceuticals Regulatory Approval Leadership Funding AI-Driven Solutions Autoimmune Drugs Regulatory Environment Computational Models Patent Expiration Translational Research Cancer Therapies Market Approval Therapeutics Antibody Discovery FDA Approvals Market Performance

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Investors are backing a push to prove AI-designed drugs in human trials by late 2026.

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

PsiThera Raises $47.5 Million and Appoints Eric Shaff as CEO to Push Oral TNF Small-Molecule Drugs

Biogen, Dayra Launch $50 Million Pact to Develop Oral Macrocyclic Peptides for Immunology

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

NRG Therapeutics Raises £50M to Advance Mitochondrial Neurodegeneration Drug Into the Clinic

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market